Direct amifostine effect on renal tubule cells in rats

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3451-3453

  Weichert Jacobsen, Klaus J ^a,b   Bannowski, Andreas ^a   Küppers, Frank ^a   Loch, Tillmann ^a   Stöckle, Michael ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; CREATININE; ENZYME; MAGNESIUM; N ACETYL BETA GLUCOSAMINIDASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY TUBULE CELL; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT;

ACETYLGLUCOSAMINIDASE; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CISPLATIN; KIDNEY DISEASES; KIDNEY TUBULES; LYSOSOMES; MALE; RATS; RATS, INBRED BN;

EID: 0033565919     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Foster-Nora, J. A., and Siden, R. Amifostine for protection from antineoplastic drug toxicity. Am. J. Health Syst. Pharm., 54: 787-800, 1997.
2. Fichtner, I., Lemm, M., Becker, M., and Berthold, F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs, 8: 174-181, 1997.
3. Yuhas, J. M., and Culo, F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by amifostine without altering its antitumor properties. Cancer Treat. Rep., 64: 57-64, 1980.
4. Treskes, M., Boven, E., Holwerda, U., Pinedo, H. M., and van der Vijgh, W. J. F. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res., 52: 2257-2260, 1992.
5. Yuhas, J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res., 40: 1519-1524, 1980.
6. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., and Glick, J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomised control trial in patients with advanced ovarian cancer. J. Clin. Oncol., 14: 2101-2112, 1996.
7. Tannehill, S. P., Mehta, M. P., Larson, M., Storer, B., Pellet, J., Kinsella, T. J., and Schiller, J. H. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a Phase II trial. J. Clin. Oncol., 15: 2850-2857, 1997.
8. Capizzi, R. L., and Oster, W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur. J. Cancer, 31: 8-13, 1995.
9. Maruhn, D., Fuchs, J., Mues, G., and Bock, K. D. Rapid colorimetric assay of β-galactosidase and N-acetyl-β-glucosaminidase in human urine. Clin. Chim. Acta, 73: 453-461, 1976.
10. Anand, A. J., and Bashey, B. Newer insight into cisplatin nephrotoxicity. Ann. Pharmacother., 27: 1519-1525, 1993.
11. Raab, W. P. Diagnostic value of urinary enzyme determinations. Clin. Chim. Acta, 18: 5-22, 1972.
12. Weichert-Jacobsen, K., Scheidt, M., Külkens, M., and Loch, T. Morphological correlates of urinary enzyme loss after extracorporeal lithotripsy. Urol. Res., 25: 257-262, 1997.
13. Skrezek, C., Bertermann, H., Schulz, F. P., König, B. NAG-ein sensitiver Marker für Nierenfunktionsstörungen. Urologe (A), 29: 27-31, 1990.